Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
企業コードSPRO
会社名Spero Therapeutics Inc
上場日Nov 02, 2017
最高経営責任者「CEO」Rajavelu (Esther)
従業員数32
証券種類Ordinary Share
決算期末Nov 02
本社所在地675 Massachusetts Ave Ste 14
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02139-3309
電話番号18572421600
ウェブサイトhttps://sperotherapeutics.com/
企業コードSPRO
上場日Nov 02, 2017
最高経営責任者「CEO」Rajavelu (Esther)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし